ArticleJournal of the International AIDS Society2025
HIV incidence and prevalence among adults in Mozambique: estimates from the Population-based HIV Impact Assessment Survey (INSIDA 2021) and district-level modelling.
Article in Journal of the International AIDS Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionAccurate information is needed to prioritize programmes and resources that address gaps in the HIV response. We examined findings from the 2021 Mozambique Population-based HIV Impact Assessment (INSIDA) survey, complemented with subnational model-based estimates of the number of new infections and district-level incidence to gauge progress in the HIV response and guide future priorities.
methodsINSIDA 2021, a nationally representative cross-sectional household survey, measured national HIV incidence, national and provincial HIV prevalence, and factors associated with HIV. Consenting adults aged 15 years and older were interviewed and tested for HIV using the national diagnostic algorithm, followed by laboratory-based confirmation of HIV status. Testing for viral load, limiting antigen avidity and the presence of antiretrovirals were used to estimate HIV incidence. The Naomi model, a Bayesian small-area estimation model combining the INSIDA 2021 survey and routine HIV service delivery data, estimated provincial and district-level HIV incidence and district-level prevalence. Weighted HIV prevalence estimates, stratified by sex, are reported and factors associated with HIV infection modelled via multivariate logistic regression.
resultsNational HIV prevalence was 12.5% (95% CI: 11.5-13.4) among adults 15 years and older, and national HIV incidence was 4.3 (95% CI: 2.3-6.3) per 1000 HIV-negative adults in 2021. Per model estimates, there were 84,000 (95% CI: 80,000-89,000) new infections per year, 55,000 among women (95% CI: 52,000-58,000) and 30,000 (95% CI: 28,000-31,000) among men. In 2023, an estimated 2.2 million (95% CI: 2,200,000-2,300,000) adults (15+ years) with HIV were living in Mozambique. District-level estimates highlighted areas of higher adult HIV prevalence and incidence in urban areas of key cities and ports, in the south, and along coastal districts in central Mozambique. Compared to men the same age, the distribution of HIV infections remains concentrated among women, particularly young women.
conclusionsMozambique continues to face a high burden HIV epidemic, with high HIV incidence associated with spatial heterogeneity. Prevention of new infections through women and young women-centred prevention programmes, treatment for men, and focusing interventions in urban areas, port cities, and coastal areas in central and southern Mozambique could contribute to reducing the HIV burden in Mozambique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.